respiratori
complic
rc
common
often
major
caus
mortal
hematopoiet
stem
cell
transplant
hsct
recent
seri
publish
group
almost
patient
undergo
hsct
suffer
least
one
signific
rc
first
year
transplant
associ
mortal
patient
obtain
earli
diagnosi
essenti
prescrib
specif
treatment
may
improv
howev
difficult
task
rang
potenti
complic
infecti
noninfecti
consider
clinic
radiolog
present
often
similar
rc
thu
often
treat
differ
empir
drug
often
unnecessari
potenti
toxic
expens
therapi
lead
antimicrobi
resist
avail
new
biomark
high
sensit
specif
infect
may
facilit
clinic
manag
rc
hsct
recipi
creactiv
protein
crp
acut
phase
protein
produc
liver
wide
use
biochem
inflammatori
recent
research
focuss
procalcitonin
pct
proadrenomedullin
proadm
two
peptid
deriv
calcitonin
gene
famili
distinct
function
although
biomark
prove
use
manag
system
infect
immunocompet
patient
valu
hsct
recipi
still
subject
thu
shown
patient
gvhd
may
exhibit
pct
posit
furthermor
differ
inflammatori
noninfecti
rc
relat
transplant
may
caus
increas
differ
cytokin
inflammatori
mediat
potenti
diminish
use
biomark
clinic
seri
publish
immunocompromis
patient
retrospect
includ
heterogen
popul
oncolog
patient
moreov
episod
evalu
alway
specif
etiolog
pulmonari
final
seri
includ
control
group
hsct
recipi
without
rc
although
neither
control
group
studi
tri
circumv
aforement
shortcom
thu
cohort
hsct
recipi
prospect
evalu
one
also
respiratori
infect
ri
identifi
microorgan
includ
final
avoid
confound
inform
mix
ri
common
occurr
hsct
recipi
aim
studi
determin
role
differ
relev
biomark
identifi
type
sever
rc
hsct
recipi
inform
provid
manuscript
come
prospect
intervent
studi
evalu
rc
cohort
consecut
hsct
recipi
followedup
year
detail
protocol
publish
provid
supplementari
inform
data
collect
includ
demograph
clinic
inform
underli
hematolog
nonhematolog
diseas
statu
transplant
patient
respiratori
symptom
fever
andor
radiolog
sign
new
infiltr
chest
xray
chestcomput
tomographi
suggest
rc
submit
seri
noninvas
procedur
sputum
cultur
nasopharyng
swab
urinari
ag
test
blood
sampl
basic
biochemistri
serolog
cytokin
determin
indic
perform
comput
tomographi
andor
fiberopt
bronchoscopi
describ
supplementari
inform
specif
primer
influenza
virus
type
b
c
respiratori
syncyti
virus
type
b
adenoviru
one
real
timepcr
specif
primer
parainfluenza
virus
coronavirus
gener
detect
rhinovirus
enterovirus
anoth
real
timepcr
carri
bal
nasopharyng
swab
clinic
indic
methodolog
obtain
cultur
sampl
diagnost
test
legionella
pneumophila
streptococcu
pneumonia
ag
detect
cmv
aspergillu
galactomannan
ag
describ
explain
previou
episod
rc
care
record
divid
infecti
noninfecti
undetermin
among
patient
present
one
complic
episod
record
consid
independ
respiratori
infect
diagnos
clinic
data
suggest
infecti
etiolog
microbiolog
agent
isol
process
sampl
clinic
cours
respons
treatment
accord
infecti
etiolog
one
microbiolog
document
bacteria
associ
one
virus
consid
mix
infect
pneumonia
diagnos
case
fever
cough
dyspnea
andor
purul
expector
new
progress
pulmonari
infiltr
explain
noninfecti
note
microbiolog
agent
isol
respiratori
sampl
requir
inclus
studi
criteria
diagnosi
noninfecti
rc
describ
supplementari
inform
publish
neutropenia
defin
anc
cellsl
accord
koya
et
classifi
ri
two
group
infect
intracellular
infect
includ
viru
tuberculosi
blood
sampl
centrifug
aliquot
frozen
subsequ
analys
level
crp
proadm
pct
measur
use
plasma
sampl
within
first
h
identif
rc
day
day
thereaft
concentr
pct
proadm
determin
use
sandwich
immunoassay
timeresolv
amplifi
cryptat
emiss
trace
technolog
pct
sensit
kryptor
proadm
kryptor
brahm
hennigsdorf
germani
creactiv
protein
measur
use
commerci
avail
immunoturbidimetr
method
siemen
medic
solut
diagnost
tarrytown
ny
usa
minimum
detect
level
ngml
pct
nmoll
proadm
mgdl
crp
cutoff
valu
ngml
pct
nmoll
proadm
mgdl
crp
determin
interleukin
il
ultrasensit
us
perform
serum
sampl
first
day
cytokin
level
measur
enzym
link
immunoassay
diasourc
inmunoassay
louvainlaneuv
belgium
us
ultrasensit
assay
invitrogen
coorpor
camarillo
ca
usa
detect
limit
pgml
pgml
us
pgml
valu
taken
upper
limit
pgml
pgml
pgml
us
pgml
continu
variabl
summar
median
interquartil
rang
compar
use
ttest
nonparametr
test
respect
categor
variabl
express
n
compar
use
fisher
exact
test
appropri
order
establish
predict
valu
biomark
differ
rc
area
curv
receiv
oper
characterist
analysi
calcul
univari
analys
includ
clinic
variabl
associ
increas
risk
mortal
identifi
previou
concentr
differ
biomark
cytokin
studi
day
perform
variabl
show
signific
result
univari
analysi
p
includ
initi
cox
proport
hazard
manual
backward
stepwis
select
use
determin
factor
associ
mortal
hazard
ratio
confid
interv
ci
calcul
proport
hazard
assumpt
test
use
logminuslog
plot
investig
lack
fit
final
model
evalu
devianc
residu
level
signific
set
statist
analys
done
use
ibm
spss
statist
version
armonk
new
york
usa
tabl
show
biomark
cytokin
level
differ
time
popul
evalu
signific
differ
leukocyt
neutrophil
count
infecti
noninfecti
rc
signific
increas
observ
level
crp
proadm
day
noninfecti
group
respect
contrast
betweengroup
cytokin
level
similar
except
day
significantli
higher
noninfecti
complic
good
correl
observ
level
pct
crp
p
proadm
p
biomarkercytokin
level
differ
patient
without
neutropenia
group
complic
level
crp
pct
proadm
day
higher
infect
compar
viral
infect
crp
mgdl
vs
mgdl
pct
ngml
vs
ngml
proadm
nmoll
vs
nmoll
p
shown
figur
level
crp
pct
proadm
tend
decreas
time
day
ri
wherea
persist
low
viral
infect
analyz
discriminatori
power
biomark
detect
ri
receiv
oper
characterist
curv
analysi
calcul
biomark
figur
proadm
highest
area
curv
ci
p
valu
nmoll
proadm
day
associ
ri
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
also
test
whether
persist
low
biomark
valu
could
rule
ri
variou
cutoff
level
maximum
valu
obtain
day
calcul
biomark
sensit
specif
ppv
npv
preclud
system
infect
result
show
persist
lower
level
first
day
crp
proadm
specif
rule
infect
particular
level
crp
mgdl
sensit
specif
ppv
level
proadm
sensit
specif
ppv
tabl
combin
pct
ngml
proadm
nmoll
confirm
infect
sensit
specif
ppv
npv
baselin
level
cytokin
evalu
differ
among
differ
ri
clinic
variabl
type
transplant
allogen
vs
autolog
intens
condit
gvhd
influenc
biomarkercytokin
level
either
noninfecti
infecti
pc
tabl
supplementari
inform
overal
mortal
patient
sixtyf
per
cent
caus
mortal
due
rc
case
procalcitonin
proadm
level
day
significantli
higher
patient
die
compar
survivor
figur
addit
crp
valu
show
signific
decreas
time
day
survivor
compar
deceas
patient
univari
analysi
show
maxpct
mgml
maxproadm
mgml
maxcrp
mgdl
gvhd
infect
etiolog
risk
factor
associ
mortal
variabl
infect
etiolog
hazard
ratio
ci
variabl
associ
mortal
multivari
analysi
result
prospect
studi
show
although
biomark
differenti
infecti
noninfecti
complic
hsct
recipi
still
use
clinic
standpoint
level
crp
pct
proadm
day
reflect
sever
rc
prognost
relev
moreov
persist
low
level
biomark
suggest
viral
infect
may
help
tailor
therapeut
regim
immunocompet
patient
biomark
pct
proadm
help
diagnosi
manag
sever
bacteri
also
febril
neutropen
patient
high
serum
pct
proadm
level
associ
diagnosi
sever
specul
hsct
recipi
biomark
might
particularli
util
due
rang
potenti
complic
infecti
noninfecti
patient
may
suffer
previou
studi
evalu
differ
biomark
set
pihusch
et
evidenc
crp
pct
level
increas
infecti
noninfecti
complic
furthermor
author
show
plasma
level
pct
use
differenti
infect
transplantrel
complic
although
detail
given
etiolog
local
infect
make
difficult
draw
comparison
seri
contrast
metaanalysi
includ
six
differ
studi
total
episod
suspect
system
infect
immedi
posttranspl
period
demonstr
crp
pct
neither
sensit
specif
enough
discrimin
system
infect
inflammatori
howev
variat
clinic
criteria
use
defin
sever
system
infect
across
studi
differ
etiolog
fever
among
group
compar
evid
sourc
present
studi
confirm
poor
discrimin
valu
biomark
diagnos
ri
cohort
patient
fact
highest
valu
biomark
found
patient
noninfecti
rc
find
relev
one
strength
present
studi
contrari
seri
episod
collect
prospect
year
followup
specif
cohort
hsct
recipi
furthermor
includ
patient
rc
specif
etiolog
sens
valid
concern
publish
trial
involv
immunocompet
immunosuppress
patient
pauciti
data
associ
microbiolog
etiolog
respiratori
tract
infect
biomark
seri
patient
noninfecti
complic
significantli
higher
level
crp
proadm
patient
ri
potenti
reason
pathway
caus
secret
biomark
infect
also
activ
inflammatori
condit
hematopoiet
sct
recipi
gvhd
exhibit
pct
posit
due
gastrointestin
damag
caus
transloc
lipopolysaccharid
secondari
product
inflammatori
moreov
engraft
syndrom
inflammatori
condit
occur
granulocyt
recoveri
hsct
character
fever
without
identifi
infecti
sourc
manifest
vascular
leak
associ
elev
concentr
sever
cytokin
seri
noninfecti
rc
due
engraft
syndrom
situat
could
partial
explain
high
level
biomark
found
consid
ri
result
confirm
previou
find
biomark
significantli
increas
ri
compar
viral
possibl
applic
biomark
clinic
practic
potenti
high
npv
measur
repetit
rule
specif
infect
regard
result
confirm
obtain
koya
et
small
seri
patient
demonstr
persist
low
valu
biomark
particularli
crp
proadm
almost
certainli
rule
infect
etiolog
agent
ri
patient
inform
may
encourag
physician
charg
withhold
specif
antibiot
prescript
potenti
seriou
advers
author
found
level
pct
allow
discrimin
episod
fever
caus
bacteria
fungi
parasit
fever
viral
reason
absenc
elev
biomark
viral
infect
well
understood
shown
secret
interferongamma
virus
induc
inhibitori
effect
pct
gene
thu
combin
aggress
attempt
pathogen
detect
togeth
determin
biomark
level
would
enhanc
antibiot
stewardship
particularli
consid
high
preval
viral
pulmonari
infect
hsct
anoth
potenti
util
biomark
clinic
manag
assess
sever
present
studi
level
pct
proadm
significantli
higher
patient
die
rc
compar
survivor
author
also
found
associ
level
pct
mortal
critic
ill
koya
et
also
identifi
associ
small
seri
hsct
recipi
inform
use
make
decis
intens
care
unit
admiss
monitor
patient
differ
limit
must
consid
proper
evalu
studi
first
lack
control
group
hsct
recipi
without
rc
flaw
certainli
hsct
recipi
undergo
differ
stage
aplast
phase
recoveri
phase
suffer
condit
acut
andor
chronic
graft
complic
presenc
mucos
may
potenti
influenc
biomark
level
nevertheless
demonstr
signific
differ
differ
type
complic
confirm
use
biomark
use
complementari
tool
manag
rc
hsct
recipi
second
decid
appli
rigor
exclus
criteria
includ
case
microbiolog
document
ri
author
awar
rel
small
number
patient
includ
mainli
due
numer
dropout
primari
cohort
owe
lack
identif
causal
microorgan
convers
owe
identif
mix
infect
caus
sever
microorgan
studi
publish
topic
includ
patient
clinic
microbiolog
diagnosi
infect
fact
repres
potenti
bia
sinc
ri
may
produc
differ
microorgan
combin
thu
make
imposs
correl
specif
microorgan
biomark
third
studi
divid
author
extracellular
intracellular
infect
awar
conflict
result
obtain
differ
author
regard
biomark
behavior
fungal
diseas
although
controversi
possibl
biomark
level
may
differ
fungal
bacteri
pulmonari
infect
studi
need
issu
final
patient
includ
studi
receiv
antibiot
andor
immunosuppress
therapi
biomark
valu
measur
therefor
assess
potenti
influenc
variabl
biomark
concentr
summari
hsct
recipi
crp
pct
proadm
differenti
infecti
noninfecti
rc
howev
biomark
estim
sever
infect
persist
low
valu
biomark
milit
infect
altern
diagnosi
viral
infect
consid
appropri
clinic
set
